New Caltech research is showing how devices implanted into people's brains, called brain-machine interfaces (BMIs), could one day help patients who have lost their ability to speak. In a new study presented at the 2022 Society ...
Nov 14, 2022
0
8
Researchers have made early progress toward a new approach to treating the deadly brain disease amyotrophic lateral sclerosis (ALS): using patients' own immune system T cells.
Oct 21, 2022
0
4
The Food and Drug Administration (FDA) recently approved the first new medication for ALS (amyotrophic lateral sclerosis) in five years—despite uncertainty about how much it helps patients with the progressive and devastating ...
Oct 18, 2022
0
12
Removing ALS (amyotrophic lateral sclerosis) patients' own dysfunctional cells, fixing them, then putting them back in patients' bodies is a safe, well tolerated process that has been shown to slow or halt disease progression ...
Oct 7, 2022
0
29
A much-debated drug for Lou Gehrig's disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.
Sep 30, 2022
0
8
In the 150 years since ALS, or amyotrophic lateral sclerosis, first came to scientific light, there remains no cure for the progressive, fatal neurodegenerative condition. But more research continues to uncover environmental ...
Sep 16, 2022
0
30
A panel of federal health advisers voted Wednesday to recommend approval for an experimental drug to treat Lou Gehrig's disease, a remarkable turnaround for the much-debated medication that was previously rejected by the ...
Sep 8, 2022
0
26
A closely watched experimental drug for Lou Gehrig's disease got an unusual second look from U.S. regulators on Wednesday, following intense pressure to approve the treatment for those with the fatal illness.
Sep 7, 2022
0
4
Amyotrophic lateral sclerosis (ALS) is an intractable disease of motor neurons for which there is no radical cure in current medicine. Without a ventilator, most people die within 3–5 years of onset due to weakness of the ...
Aug 22, 2022
0
6
"Understanding Pseudobulbar Affect," the inaugural publication of the new Insights & Implications in Gerontology series from The Gerontological Society of America, addresses an often overlooked or misunderstood condition ...
Aug 11, 2022
0
21
